Allergists, Biologists, Cell Biologists, Cytologists, Immunologists, Infectious Disease Specialists, Molecular Biologists, Oncologists
mAbs is a multi-disciplinary journal dedicated to the art and science of antibody research and development. The journal has a strong scientific and medical focus, but also strives to serve a broader readership. The articles are thus of interest to scientists, clinical researchers, and physicians, as well as the wider mAb community, including our readers involved in technology transfer, legal issues, investment, strategic planning and the regulation of therapeutics.
mAbs publishes relevant and timely original research, as well as authoritative overviews, commentary and perspectives providing context for the work presented in mAbs and for key results published elsewhere. Original research papers may cover all topics important in the antibody field, including studies of targeted proteins that are not antibody-based. Reviews, commentaries and perspectives on any aspect of antibody R&D are welcome. Relevant topics include (but are not be limited to):
Antibody engineering and selection; Targets relevant to cancer, immune-mediated disorders, and other diseases;
Non-clinical studies of antibodies, e.g., mechanism of action studies, safety and efficacy studies in animals; Manufacturing; Clinical studies; Regulatory review of antibody therapeutics; Post-approval topics, e.g., pricing, reimbursement and markets; Patents; Emerging markets for antibody therapeutics, including China and India.